Gene · 7357
Papers2,116
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 2,116
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A differential proteomics study of cerebrospinal fluid from individuals with Niemann-Pick disease, Type C1. | Proteomics | 2023 | 36638187 | PubTator, text mining | PubMed |
| Suicidal attempt with eliglustat overdose. | JIMD Rep | 2023 | 36636596 | PubTator, text mining | PubMed |
| Pediatric hepatocellular carcinoma associated with Niemann-Pick disease type C: Case report and literature review. | JIMD Rep | 2023 | 36636588 | PubTator, text mining | PubMed |
| Salvianolic acid B suppresses hepatic fibrosis by inhibiting ceramide glucosyltransferase in hepatic stellate cells. | Acta Pharmacol Sin | 2023 | 36627345 | PubTator, text mining | PubMed |
| The Consequences of GBA Deficiency in the Autophagy-Lysosome System in Parkinson's Disease Associated with GBA. | Cells | 2023 | 36611984 | PubTator, text mining | PubMed |
| Molecular profile and peripheral markers of neurodegeneration in patients with Niemann-Pick type C: Decrease in Plasminogen Activator Inhibitor type 1 and Platelet-Derived Growth Factor type AA. | Arch Biochem Biophys | 2023 | 36608914 | PubTator, text mining | PubMed |
| Inhibitors of Glucosylceramide Synthase. | Methods Mol Biol | 2023 | 36587085 | PubTator, text mining | PubMed |
| Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cells. | Biochem Biophys Res Commun | 2023 | 36586187 | PubTator, text mining | PubMed |
| Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial. | Am J Kidney Dis | 2023 | 36535535 | PubTator, text mining | PubMed |
| A sensitive method for determining UDP-glucose: ceramide glucosyltransferase (UGCG) activity in biological samples using deuterated glucosylceramide as acceptor substrate. | Glycobiology | 2023 | 36504340 | PubTator, text mining | PubMed |
| ST3GAL5-catalyzed gangliosides inhibit TGF-β-induced epithelial-mesenchymal transition via TβRI degradation. | EMBO J | 2023 | 36504224 | PubTator, text mining | PubMed |
| Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study. | Mol Genet Metab | 2023 | 36481125 | PubTator, text mining | PubMed |
| Targeting Multiple Hallmarks of Skin Aging: Preclinical and Clinical Efficacy of a Novel Growth Factor-Based Skin Care Serum. | Dermatol Ther (Heidelb) | 2023 | 36374431 | PubTator, text mining | PubMed |
| A Review of Radiation-Induced Alterations of Multi-Omic Profiles, Radiation Injury Biomarkers, and Countermeasures. | Radiat Res | 2023 | 36368026 | PubTator, text mining | PubMed |
| Targeting UGCG Overcomes Resistance to Lysosomal Autophagy Inhibition. | Cancer Discov | 2023 | 36331284 | PubTator, text mining | PubMed |
| The Sphingolipids Metabolism Mechanism and Associated Molecular Biomarker Investigation in Keloid. | Comb Chem High Throughput Screen | 2023 | 36321232 | PubTator, text mining | PubMed |
| Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial. | Brain | 2023 | 36256599 | PubTator, text mining | PubMed |
| Current advancements and future perspectives of long noncoding RNAs in lipid metabolism and signaling. | J Adv Res | 2023 | 35973552 | PubTator, text mining | PubMed |
| Fabry Disease: Current and Novel Therapeutic Strategies. A Narrative Review. | Curr Neuropharmacol | 2023 | 35652398 | PubTator, text mining | PubMed |
| A novel strategy for delivering Niemann-Pick type C2 proteins across the blood-brain barrier using the brain endothelial-specific AAV-BR1 virus. | J Neurochem | 2023 | 35554935 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7357/papers?page=14